ProCE Banner Activity

CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM

Slideset Download
Conference Coverage

Initial results from the phase Ib/II study suggest ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, showed promising efficacy and a manageable safety profile in heavily pretreated patients with R/R MM.

Released: December 14, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology